KOSDAQBiotech & Pharma397030

AprilBio

₩11,480▲ 0.61%2026-11-18 close
Market Cap
₩316.4B
Turnover
₩700M
Volume
60K
Shares out.
27.6M
PER
—
PBR
1.0×
EPS
-₩356
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

AprilBio: KRW 430 billion in cash, licensing is the test

A 2026 capital raise lifted liquidity to about KRW 430 billion, yet disclosed operating losses have run for five straight quarters, so whether the targeted 2027 licensing deals close is the next checkpoint.

  1. 1

    After the KRW 346.8 billion third-party allotment was paid in July 2026, liquidity stood at about KRW 430 billion as of Q3 2026.

  2. 2

    2025 revenue fell 92.1% year on year to KRW 2.17 billion, and the company swung to an operating loss of KRW 7.26 billion.

  3. 3

    On disclosed figures, operating losses have run for five consecutive quarters from Q3 2025 to Q3 2026, with a KRW 3.35 billion loss in Q3 2026.

  4. 4

    The company aims to license three new pipelines early during 2027 and has set a 2027 R&D budget of about KRW 50.7 billion.

  5. 5

    Because the last four quarters combined to an attributable net loss of KRW 8.65 billion, PER is not calculated, while the price-to-book ratio sits below 1x.

02

Business structure

AprilBio was founded in 2013 as a drug discovery company and listed on KOSDAQ in July 2022. Built on its SAFA platform, it out-licensed an autoimmune candidate to Lundbeck of Denmark in 2021 and another candidate to a U.S. company in 2024. The two deals together were reported at up to USD 923 million.

The company now centers on REMAP, an upgraded successor to SAFA, and is extending into bispecific antibodies, siRNA and antibody-drug conjugates (ADCs). Three new pipelines are in focus.

APB-I-005 is a bispecific antibody that blocks TL1A and IL-23p19 together, and the company said it reduced inflammation and tissue damage in acute and chronic colitis animal models.

APB-O-001 is a dual-target PCSK9 and ApoC3 siRNA therapy developed with a domestic RNA partner, and the company is independently replicating its partner's data.

APB-A-001 is a REMAP-based ADC targeting c-Met and VEGF, which the company said showed stronger tumor growth inhibition than an existing c-Met-targeted ADC in lung cancer xenograft mice. Its customers are global pharmaceutical licensees, and revenue depends heavily on when deals are signed.

In the nine months to Q3 2025, separate-basis results were pressured by lower anticancer technology-transfer revenue. Competition overlaps with other companies across antibody, siRNA and ADC modalities in autoimmune, metabolic and oncology areas.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩0-₩2.5B—
2025Q4₩0-₩2B—
2026Q1₩700M-₩2.2B−302.3%
2026Q2₩0-₩2.9B—
2026Q3₩600M-₩3.4B−562.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩200M-₩11.5B-₩9B−5737.2%−13.0%2.8%
2023₩0-₩13.4B-₩14.1B—−24.5%38.0%
2024₩27.5B₩16.9B₩20B61.3%22.0%9.5%
2025₩2.2B-₩7.3B-₩9.7B−334.4%−10.1%0.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On disclosed figures, revenue was KRW 200 million in 2022 and KRW 27.5 billion in 2024, with no data for 2023. Revenue then fell to KRW 2.17 billion in 2025, down 92.1% year on year. Separate-basis results for the nine months to Q3 2025 pointed to lower anticancer technology-transfer revenue as the main driver.

Operating losses of KRW 11.5 billion in 2022 and KRW 13.4 billion in 2023 persisted before an operating profit of KRW 16.9 billion in 2024 turned the year positive. The company returned to an operating loss of KRW 7.26 billion in 2025, and its operating margin moved from 61.3% in 2024 to -334.4% in 2025.

Attributable net income turned positive at KRW 20 billion in 2024, then became an attributable net loss of KRW 9.73 billion in 2025. The 2024 attributable profit exceeded that year's operating profit, and the same year coincided with the 2024 out-licensing deal with the U.S. company.

Net income including non-controlling interests was KRW 20 billion in 2024 and a net loss of KRW 9.73 billion in 2025. Operating cash flow was KRW 22 billion in 2024 and minus KRW 3.34 billion in 2025.

Quarterly operating losses widened in 2026, from KRW 2 billion in Q4 2025 to KRW 2.19 billion in Q1 2026, KRW 2.92 billion in Q2 and KRW 3.35 billion in Q3. Quarterly revenue was KRW 725 million in Q1 2026 and KRW 596 million in Q3, with no Q2 figure.

Attributable net income was KRW 201 million in Q1 2026, but the company returned to a KRW 1.99 billion net loss in Q2 and a KRW 4.6 billion loss in Q3, which was narrower than the KRW 4.96 billion loss a year earlier. The attributable net loss for the last four quarters totals KRW 8.65 billion.

05

Industry analysis

Global pharma licensing is shifting toward earlier-stage assets. According to DealForma data cited by the company, the share of candidates at preclinical or Phase 1 stage among those in-licensed by large global pharma rose from 59% in 2024 to 69% in the first half of 2026.

The company builds its plan on this trend, aiming to license assets before IND filing. In autoimmune disease, Tulisokibart, a TL1A-targeting drug, met its primary endpoint in Phase 3 in June 2026, and IL-23p19 is already an approved target in inflammatory bowel disease, which the company cites as support for APB-I-005.

Lundbeck halted a Phase 1b trial of APB-A1 in thyroid eye disease in August 2026 because the effect fell short of expectations, though reports say its safety and tolerability were rated favorably.

In a November 3, 2026 report carried by the press, Kim Sun-ah of Hana Securities was reported to see clinical momentum and new licensing prospects building in 2027.

Compared with peers, AprilBio's model is closer to Alteogen's platform-licensing approach than to Samsung Biologics' contract manufacturing, so its revenue structure differs. Its KRW 430 billion in cash could fund parallel development and external asset in-licensing.

The SAFA platform has proof of concept in the clinic, but REMAP-based assets remain largely at the preclinical stage.

06

Outlook

The company's 2027 plan rests on three pillars. First, it has set a 2027 R&D budget of about KRW 50.7 billion to develop three assets in parallel.

Second, it aims to bring all three assets to licensing discussions before IND filing, and it said it intends to shorten the roughly three-year gap between its past licensing deals.

Third, it plans to expand in-licensing of preclinical and clinical assets, starting with its ongoing collaborations with two domestic partners. APB-I-005 is targeted for an IND filing in Q1 2028 after toxicology studies in 2027.

For APB-A-001, the choice between in-house clinical development and early licensing will depend on pharmacokinetic and pharmacodynamic data added in 2027. For APB-O-001, the company plans licensing activity once independent replication of its partner's animal data is complete.

Press reports say the company is considering linker technology for AOC development as a key in-licensing target. CEO Cha Sang-hoon said cash alone does not raise corporate value and that the key is how quickly the funds turn into results. Headcount rose from about 28 before the investment to 49 now, with further hiring planned.

07

Valuation

PER
—
PBR
1.0×
ROE
-4.6%
EPS
-₩356
BPS
₩12,550
Dividend per share
₩0

Because the last four quarters combined to an attributable net loss of KRW 8.65 billion, PER cannot be calculated on earnings. The price-to-book ratio sits below 1x, meaning the shares trade under book equity.

Equity at the end of 2025 was KRW 96.3 billion, all of it attributable to shareholders of the parent, against total liabilities of KRW 804 million. The July 2026 capital raise is not included in year-end 2025 equity, so post-raise equity will be checked in the next periodic report.

Setting the KRW 430 billion of cash at Q3 2026 beside market capitalization is a starting point for asking what the share price already reflects. Over several years, earnings moved from a profit in 2024 to a loss in 2025, and operating losses widened through 2026. Dividend payouts are effectively nil.

With earnings-based multiples unavailable, price-to-book and pipeline value have become the focus of the valuation discussion.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Cash capacity and low leverage

Liquidity stood at about KRW 430 billion as of Q3 2026, against total liabilities of KRW 804 million and a debt-to-equity ratio of 0.8% at the end of 2025. All KRW 96.3 billion of year-end 2025 equity belongs to shareholders of the parent.

The company says the cash covers a KRW 50.7 billion 2027 R&D budget and still leaves room for external asset in-licensing.

Three pipelines and licensing targets

The company targets bringing APB-I-005, APB-O-001 and APB-A-001 to licensing talks before IND filing in 2027. The DealForma data it cites, showing the preclinical and Phase 1 share of big-pharma in-licensing rising from 59% in 2024 to 69% in the first half of 2026, fits this approach. It also plans to shorten the gap between licensing deals from about three years.

A track record of out-licensing

Deals with Lundbeck in 2021 and a U.S. company in 2024 were reported at up to USD 923 million in total value. Lundbeck halted a trial in August 2026, yet its safety and tolerability are reported as favorable. The company argues that this licensing record can support talks on new assets.

09

Bear factors

Continued losses and falling revenue

Revenue fell 92.1% in 2025 to KRW 2.17 billion, and operating losses reached KRW 7.26 billion. In Q3 2026, revenue was KRW 596 million and the operating loss KRW 3.35 billion, extending a run of five consecutive quarterly operating losses on disclosed figures. As operating losses continue, the attributable net loss has also built up over the last four quarters.

Uncertainty in preclinical assets

Efficacy data for APB-I-005 and APB-A-001 has only been disclosed from animal studies, and clinical entry follows the Q1 2028 IND target. For APB-O-001, the efficacy metrics disclosed so far come from the partner's experiments, and the company is running its own replication. Until licensing deals are signed, the value of these assets rests on unproven data.

Share price path and governance change

After Lundbeck halted its trial in August 2026, press reports said the share price was briefly hit, and CEO Cha Sang-hoon apologized to shareholders for the decline at the R&D Day.

After payment in July 2026, the largest shareholder became an investment vehicle linked to IMM, while TKG Huchems exercises management control under a joint investment agreement.

10

Risk factors

Delayed or unsigned licensing

The three early licensing deals targeted for 2027 are company goals, and signing depends on outside negotiations. The planned 2027 R&D budget of about KRW 50.7 billion far exceeds 2025 revenue of KRW 2.17 billion, so if deals slip, R&D spending weighs on profit. Until deal values and milestone structures are disclosed, the timing of revenue remains uncertain.

Clinical and efficacy data validation

APB-O-001 is undergoing independent replication of partner data, while APB-I-005 and APB-A-001 are at animal study and preclinical PK/PD stages. Lundbeck's halt of APB-A1 shows that results can differ across trial stages. If data falls short, licensing terms and overall pipeline value would both be affected.

Governance and share supply

Shares allotted in the 2026 third-party offering are subject to a one-year lock-up from their August 5, 2026 scheduled delivery date, so supply could become a factor around August 2027.

The largest shareholder is now an IMM-linked vehicle, and TKG Huchems exercises management control, which changes the decision-making structure from the founder-centered model. How this affects licensing negotiations has yet to be seen.

11

What to watch next

  1. Late March 2027

    The deadline for the 2026 annual report. It will be the first periodic report to show audited full-year 2026 results, the Q4 2026 operating loss trend and equity after the capital raise.

  2. Mid-May 2027

    The deadline for the Q1 2027 quarterly report. It is the point to check whether operating losses continue and whether any licensing deal shows up in revenue.

  3. During 2027

    Whether the three assets sign licensing deals and on what terms (upfront, milestones, royalties). The company has named this as the key to its valuation, and deal size will shape the revenue structure.

  4. Around August 2027

    Around when the one-year lock-up on shares from the July 2026 third-party allotment ends. It is the point to watch for changes in trading supply.

  5. Q1 2028

    The target quarter for the IND filing of APB-I-005. Whether toxicology results in 2027 keep this schedule is the item to check.

12

Overall view

AprilBio raised KRW 346.8 billion in 2026, lifting liquidity to about KRW 430 billion, and has moved its R&D to parallel development aimed at licensing three new pipelines in 2027. Financial leverage is low, with total liabilities of KRW 804 million and a debt-to-equity ratio of 0.8% at the end of 2025.

Disclosed results, however, show 2025 revenue of KRW 2.17 billion and an operating loss of KRW 7.26 billion, and operating losses have run for five consecutive quarters from Q3 2025 to Q3 2026. These losses have accumulated into the attributable net loss over the last four quarters.

On the positive side, the company's licensing record, its cash and the trend toward earlier-stage in-licensing are cited. On the negative side, persistent losses, unproven preclinical data and the Lundbeck trial halt are cited.

Its three new candidates are still at animal or preclinical stages, so independent replication of efficacy data and signing of deals are the central checks. CEO Cha Sang-hoon has said cash alone does not raise corporate value.

Whether the 2027 licensing targets turn into signed contracts will determine how the company's value is assessed, and the answer should appear in 2027 disclosures and the March 2027 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. ebn.co.kr
  2. news.mtn.co.kr
  3. thevc.kr
  4. hankooki.com
  5. newsway.co.kr
  6. financialpost.co.kr
  7. supple.kr
  8. comp.wisereport.co.kr
  9. dealsite.co.kr
  10. m.news.nate.com
  11. digitaltoday.co.kr
  12. hankyung.com
  13. newspim.com
  14. thebionews.net
  15. newstown.co.kr
  16. medicaldaily.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis